Skip to main content
Signal8
Launch Terminal

SIGA TECHNOLOGIES INC (SIGA)

SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.

Sector: Pharmaceutical Preparations

Industry: Drug Manufacturers - Specialty & Generic

SIGA Technologies, Inc. logo

SIGA Technologies, Inc.

NASDAQ:SIGAHealthcare
-4.40%$3.04
AH$3.02-0.66%vs close
Mkt Cap$218.42M
Float46.4M
O/S71.85M
Vol
$ Vol
RVOL
Inst Own48.5%
SI7.7%
Earnings
Div Yield19.74%
Dilution
SIGA Technologies, Inc. logoNASDAQ:SIGA$3.04-4.40%
Phase Distribution
9 lead-sponsored trials·1 active·7 completed
Phase 12
Phase 22
Phase 32
Phase 42
Not applicable1
(2 more as collaborator)
Status Overview
Active, not recruiting1
Completed7
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Completed

    Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG

    Tpoxx

    Smallpox

    Enrollment
    34
    Start
    Jul 2019
    Primary Completion
    Dec 2019
    Completion
    Dec 2019
    NCT04392739
  • Phase 4
    Completed

    Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

    Tecovirimat, sevelamer carbonate oral tablet

    Smallpox

    Enrollment
    44
    Start
    Jun 2022
    Primary Completion
    Dec 2022
    Completion
    Apr 2023
    NCT04485039
  • Phase 3
    Completed

    A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat

    tecovirimat

    Smallpox

    Enrollment
    449
    Start
    Jun 2015
    Primary Completion
    Aug 2016
    Completion
    Aug 2016
    NCT02474589
  • Phase 3
    Completed

    Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days

    TPOXX

    Smallpox

    Enrollment
    467
    Start
    Mar 2022
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT04971109
  • Phase 2
    Completed

    Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246

    ST-246 400 mg, ST-246 600 mg

    Orthopoxviral Disease

    Enrollment
    107
    Start
    Jun 2009
    Primary Completion
    Jan 2010
    Completion
    Jan 2010
    NCT00907803
  • Phase 2
    Active, not recruiting

    Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS

    Tecovirimat, Smallpox and Mpox Vaccine

    Smallpox

    Enrollment
    100
    Start
    Apr 2022
    Primary Completion
    Jan 2027est.
    Completion
    Jan 2027est.
    NCT04957485
  • Phase 1
    Completed

    Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers

    ST-246, Placebo

    Healthy

    Enrollment
    30
    Start
    Feb 2007
    Primary Completion
    Feb 2008
    Completion
    Feb 2008
    NCT00431951
  • Phase 1
    Completed

    Phase I Trial of an Investigational Small Pox Medication

    ST-246 Days 1 - 3, ST-246 Days 11 - 13

    Orthopoxviral Disease, Smallpox +1

    Enrollment
    12
    Start
    Aug 2008
    Primary Completion
    Oct 2008
    Completion
    Oct 2008
    NCT00728689
  • Observational
    Withdrawn

    A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox

    TPOXX 200Mg Capsule

    Smallpox

    Enrollment
    0
    Start
    Jan 2020
    Primary Completion
    Sep 2024est.
    Completion
    Sep 2024est.
    NCT03972111
Search ClinicalTrials.gov for “Siga Technologies”